Summit Therapeutics (SMMT) Short term Debt (2019)

Summit Therapeutics' (SMMT) quarterly Short term Debt came in at $105000.0 in Q4 2019.

Summit Therapeutics (SMMT) Short term Debt (2019) Analysis & Trends

Summit Therapeutics (SMMT) has 1 years of Short term Debt data on file, last reported at $105000.0 in Q4 2019.

Quarterly Short term Debt changed N/A year-over-year to $105000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $105000.0 (changed N/A YoY) and the FY2019 annual result came in at $105000.0, changed N/A from the prior year.
Short term Debt was little changed at $105000.0 in Q4 2019.
In the past five years, Short term Debt ranged from a high of $105000.0 in Q4 2019 to a low of $105000.0 in Q4 2019.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Summit Therapeutics	10.59 Bn	9.90 Bn	-

Historic Data

Download Data

Date	Value
Dec 31, 2019	105,000.00